ArticleIDCases2025
Transmission of human herpesvirus-8 through liver transplantation and development of post-transplantation Kaposi sarcoma: A case report.
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Kaposi sarcoma is a vascular tumour associated with human herpesvirus-8 (HHV-8) infection. Due to immunosuppressive treatment, solid organ transplant recipients infected with HHV-8 have increased risk of Kaposi sarcoma. The risk of being infected with HHV-8 is associated with higher age, male sex, non-White ethnicity, being a man who has sex with men (MSM) and use of recreational drugs. Post-transplant Kaposi sarcoma is rare in HHV-8 low-prevalence areas. We report the first case of a liver transplant recipient developing Kaposi sarcoma following donor-transmitted HHV-8 infection in Denmark. Case presentation: A 51-year-old male underwent uncomplicated liver transplantation at Copenhagen University Hospital - Rigshospitalet, and received standard immunosuppressive treatment with tacrolimus, mycophenolate mofetil and prednisolone. Five months post-transplantation the patient was admitted with abdominal pain, diarrhoea, and dehydration. Ultrasound imaging and PET/CT scan revealed multiple liver tumours. Biopsy from liver tumour diagnosed visceral post-transplantation Kaposi sarcoma. Kaposi sarcoma was successfully treated with reduction of immunosuppressive treatment and conversion from tacrolimus to everolimus, resulting in viral clearance and complete metabolic and structural tumour response. A review of the donor post-transplantation revealed multiple risk factors for being infected with HHV-8, with subsequent analysis confirming the donor was positive for HHV-8. Discussion: Even in low-prevalence areas, there are benefits of targeted screening for HHV-8 in high-risk organ donors and recipients described in the literature and highlighted in the current case. Post-transplantation Kaposi sarcoma due to HHV-8 may be managed with reduction in immunosuppressive treatment and conversion from calcineurin inhibitors to mTOR inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.